利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.013 秒)

    Antisense oligonucleotide modulation of human HER-2 expression
    2.
    发明授权
    Antisense oligonucleotide modulation of human HER-2 expression 失效
    人HER-2表达的反义寡核苷酸调节

    公开(公告)号：US5968748A

    公开(公告)日：1999-10-19

    申请号：US48804

    申请日：1998-03-26

    申请人： C. Frank Bennett ,  Allan Lipton ,  Lois M. Witters

    发明人： C. Frank Bennett ,  Allan Lipton ,  Lois M. Witters

    IPC分类号： A61K38/00 ,  C12N15/113 ,  C12Q1/68 ,  C07H21/04 ,  C12N15/85

    CPC分类号： C12N15/1138 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/334 ,  C12N2310/346

    摘要： Compounds, compositions and methods are provided for inhibiting the expression of human HER-2 (also known as c-neu, ErbB-2 and HER-2/neu). The compositions comprise antisense oligonucleoptides targeted to nucleic acids encoding HER-2. Methods of using these oligonucleotides for inhibition of HER-2 expression and for treatment of diseases such as cancers associated with overexpression of HER-2 are provided. Methods of inhibiting other growth factor receptors using antisense oligonucleotides targeted to nucleic acids encoding HER-2 are also provided.

    摘要翻译： 提供化合物，组合物和方法用于抑制人HER-2（也称为c-neu，ErbB-2和HER-2 / neu）的表达。 组合物包含靶向编码HER-2的核酸的反义寡核苷酸。 提供了使用这些寡核苷酸抑制HER-2表达和治疗诸如与HER-2过度表达相关的癌症的疾病的方法。 还提供了使用靶向编码HER-2的核酸的反义寡核苷酸抑制其它生长因子受体的方法。

    Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples
    4.
    发明授权
    Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples 有权
    基于表皮生长因子受体（EGFR）细胞外结构域（ECD）分析物，单独或与其他分析物组合在体液样品中的水平的癌症患者监测的测定

    公开(公告)号：US07473534B2

    公开(公告)日：2009-01-06

    申请号：US10375371

    申请日：2003-02-27

    申请人： Walter P. Carney ,  Peter J. Hamer ,  Allan Lipton ,  Kim Leitzel ,  Suhail M. Ali

    发明人： Walter P. Carney ,  Peter J. Hamer ,  Allan Lipton ,  Kim Leitzel ,  Suhail M. Ali

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57488 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57449 ,  G01N2333/485 ,  G01N2333/71 ,  G01N2800/52

    摘要： The present invention describes clinically and medically important methods of monitoring the outcome of a cancer patient who is suffering from disease or who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease or cancer treatment effectiveness in a cancer patient by measuring the level of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment, wherein a decrease in the level of the ECD of the EGFR in the cancer patient compared with the level of the ECD of the EGFR in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient. As another aspect of determining disease outcome and survival, the invention further provides assessing both EGFR and HER-2/neu levels, in combination, in a patient sample. A finding of decreased levels of EGFR concomitantly with elevated or increased levels of HER-2/neu relative to control levels indicates poor outcome and short time to progression.

    摘要翻译： 本发明描述了临床和医学上重要的监测患有疾病或正在接受他或她的疾病的治疗或治疗的癌症患者的结果的方法。 更具体地，本发明提供了通过测量取自癌症患者的样品中表皮生长因子受体（EGFR）的细胞外结构域（ECD）的水平来监测癌症患者的疾病进展或癌症治疗有效性的方法 ，优选在治疗前，治疗开始时和治疗期间的不同时间间隔，其中与正常对照个体中EGFR的ECD水平相比，癌症患者中EGFR的ECD水平降低 作为癌症进展或进展的指标和/或患者缺乏治疗有效性。 作为确定疾病结果和存活的另一方面，本发明进一步提供了在患者样品中组合评价EGFR和HER-2 / neu水平。 与控制水平相比，伴随HER-2 / neu水平升高或升高的EGFR水平降低的发现表明结果差，进展时间短。

    Platelet derived cell growth factor
    8.
    发明授权
    Platelet derived cell growth factor 失效
    血小板衍生细胞生长因子

    公开(公告)号：US4350687A

    公开(公告)日：1982-09-21

    申请号：US234448

    申请日：1980-02-10

    申请人： Allan Lipton ,  Nancy Kepner

    发明人： Allan Lipton ,  Nancy Kepner

    IPC分类号： A61K38/00 ,  C07K14/49 ,  A61K37/02 ,  C07G7/00 ,  C12N5/00 ,  C12P21/00

    CPC分类号： C07K14/49 ,  A61K38/00

    摘要： A purified cell growth factor is produced which comprises a substantially purified glycoproteinaceous factor from platelets which has mitogenic activity toward transformed cells, a molecular weight of 3,000-5,000 daltons and a pI of 7.8-8.3. The growth factor is stable to treatment with 4M guanidine hydrochloride, and is heat labile when treated at 100.degree. C. for 5 minutes.

    摘要翻译： 产生纯化的细胞生长因子，其包含来自血小板的基本上纯化的糖蛋白因子，其对转化细胞具有促有丝分裂活性，分子量为3,000-5,000道尔顿，pI为7.8-8.3。 生长因子对于4M盐酸胍处理稳定，在100℃下处理5分钟时热不稳定。